In the setting of a clinical trial evaluating the anti-HIV-1 antibody 3BNC117, Cohen et al. demonstrate that rebound viruses that emerge following interruption of antiretroviral therapy are distinct from circulating latent viruses. However, rebound viruses often appear to be recombinants between isolated latent viruses. By incorporating the possibility of recombination, 63% of the rebound viruses could have derived from the observed latent reservoir. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating reservoir, but instead appear to represent recombinants.
Introduction
Small molecule antiretroviral drugs are highly effective in suppressing HIV-1 viremia. However, therapy needs to be lifelong because it fails to eliminate a reservoir of latent HIV-1 viruses integrated into the genome of infected cells (Chun et al., 1997; Finzi et al., 1997) . Significant efforts are currently focused on therapies, including immunotherapies, to target the reservoir to achieve sustainable ART-free remission (Churchill et al., 2016; Martin and Siliciano, 2016) .
The immunotherapeutic agents that are clinically most advanced in this respect are newly discovered broad and potent monoclonal antibodies (bNAbs) that recognize the HIV-1 envelope protein expressed on the surface of infected cells and virions (Halper-Stromberg and Nussenzweig, 2016) . These new antibodies protect against and suppress infection in mice and macaques (Barouch et al., 2013; Gautam et al., 2016; Halper-Stromberg et al., 2014; Horwitz et al., 2013; Klein et al., 2012; Shingai et al., 2014; Shingai et al., 2013) . In human clinical trials, they suppress viremia, and delay viral rebound in the setting of treatment interruption (Bar et al., 2016; Caskey et al., 2015; Caskey et al., 2017; Lynch et al., 2015; Scheid et al., 2016) . Most importantly, immunotherapy with bNAbs differs from small molecule drugs in that antibodies can eliminate circulating virus and infected cells through Fc-mediated effector mechanisms (Halper-Stromberg et al., 2014; Igarashi et al., 1999; Lu et al., 2016) . In addition, bNAb administration is associated with development of potent antiviral CD8 + T cell immunity in macaques (Nishimura et al., 2017) .
Infusion of VRC01, an anti-CD4-binding site antibody, in the setting of continued ART did not measurably alter the size of the latent reservoir in 6 individuals (Lynch et al., 2015) . However, the sensitivity of circulating reservoir viruses to VRC01 was not determined and the relationship of latent viruses to plasma viruses that emerge during an analytical treatment interruption (ATI) was not examined.
Here we evaluate the effects of 3BNC117, a broad and potent anti-CD4-binding site bNAb (Caskey et al., 2015; Scheid et al., 2016; Scheid et al., 2011) in the setting of continued ART administration and during treatment interruption. We report on the dynamics of resistant and sensitive viruses in the latent HIV reservoir over a 6-month period prior to ATI, and the relationship between latent and rebound viruses.
Results

Study Participants
Fifteen HIV-1-infected participants virologically suppressed on ART were enrolled and underwent ATI (Table 1, Supplementary Table 1 , and Supplementary Fig. 1 ). Participants received four intravenous infusions of 3BNC117 at 30 mg/kg at week 0, week 12, week 24, and week 27 (Fig. 1a) . Leukapheresis was performed at week -2 and week 23 to collect PBMC for by leukapheresis at weeks -2 and 23, during which time the participants remained on suppressive ART and received 2 infusions of 3BNC117 at weeks 0 and 12, maintaining detectable 3BNC117 serum levels for most of the 23-week period. Q 2 VOA was performed for 10 participants: the first 9 to enter the ATI phase of the trial (with the exception of participant 604, whose virus could not be grown in Q 2 VOA), and participant 616. Nine of these participants had samples available from both week -2 and week 23 (participant 609 declined the week 23 leukapheresis).
The infectious units per million (IUPM) of latently infected CD4 + T cells among these nine participants at weeks -2 and 23 ranged from 0.33-1.9 and 0.47-4.0, respectively. We found no significant changes in IUPM between the two time points for any participant (defined by a > 6-fold change (Crooks et al., 2015) (Fig. 1b) ). We conclude that 2 doses of 3BNC117 administered over 23 weeks in the setting of suppressive ART does not measurably reduce the size of the latent reservoir.
The latent reservoir is dynamic over a 6-month period
To examine the molecular nature of the replication-competent viruses in the latent reservoir, we analyzed the latent viruses isolated by Q 2 VOA at weeks -2 and 23. An average of 1.18 x 10 8 CD4 + T lymphocytes were cultured per participant per time point, yielding an average of 40 independent env sequences per participant per time point (Supplementary Table 4 ). Phylogenetic analysis showed that each participant analyzed was infected with epidemiologically unrelated clade B viruses ( Supplementary Fig. 3 ). The clonal structure of the latent reservoir differed among the participants analyzed and could be divided into three categories: dominated by a single clone (603, 610, 616) , dominated by multiple clones (601, 602, 605, 611, 613) , or non-clonal (608) (Fig. 1c) . Overall, 57% of viral sequences in the reservoir were clonal, which is consistent with prior studies (Bui et al., 2017; Hosmane et al., 2017; Lee et al., 2017; Lorenzi et al., 2016) .
We observed clonal fluctuations that varied from appearance or disappearance of clones to large alterations in their relative size. For example, a clone from participant 602 comprised 11% of the circulating reservoir at week -2, but 42% of the circulating reservoir at week 23 (Fig. 1c) .
Utilizing the Q 2 VOA data and Bayesian inference, we inferred the IUPM of each clone at each time point. In 5 of the 9 participants, there were statistically significant fluctuations within the circulating reservoir, indicating that the observed changes in the composition of the reservoir between the 2 time points was very unlikely to be the result of finite sampling alone (Fig. 1d ).
However, these fluctuations were not correlated with the sensitivity of the outgrown viruses to 3BNC117, with some resistant clones decreasing in size, and some sensitive clones increasing in size ( Fig. 1d) . We conclude that the size of latent reservoir clones in circulation fluctuates over a 6-month interval in individuals treated with 3BNC117 while on suppressive ART, and that this effect is independent of bNAb sensitivity.
3BNC117 delays viral rebound in sensitive participants
Participants received 2 additional doses of 3BCN117 at weeks 24 and 27 in the setting of ART interruption (Fig. 1a ). Viral rebound occurred between 2 and 17 weeks thereafter ( Supplementary   Fig. 4 ). The average time to rebound was 5.5 weeks, which was a significant delay compared to historical controls (p < 0.0001) (Fig 2a) . The size of the latent reservoir, as determined by Q 2 VOA at week 23, did not correlate with time to rebound (Fig. 2b ).
For many participants, latent viruses exhibited a range of sensitives to 3BNC117 and other bNAbs that target distinct epitopes, as previously shown (Lorenzi et al., 2016) (Supplementary   Tables 5 and 6 ). For example, viruses obtained by Q 2 VOA for participant 601 ranged from sensitive (IC 50 = 1.45 μg/ml) to completely resistant (IC 50 > 50 μg/ml) (Fig. 2c , blue circles).
Participant 616, who demonstrated the longest delay in time to rebound, harbored a reservoir that was both highly sensitive and of restricted neutralization diversity (Fig. 2c) . The 3BNC117 IC 50 titer of the most resistant latent virus isolated from each of these participants correlated with time to rebound (p = 0.04, R 2 = 0.44) (Fig. 2d) . Thus, pre-existing resistance within the latent reservoir is predictive of bNAb efficacy.
To assess the neutralization sensitivity of rebound viruses, single genome analysis (SGA) was performed on plasma, and outgrowth cultures were performed using PBMCs obtained at the time of rebound. For 7 participants, outgrown viruses from the time of rebound were identical to plasma SGA viruses (Supplementary Fig. 5) . Neutralization titers were then determined for the rebound viruses isolated from culture (Cohen et al., 2017) . Overall, the 3BNC117 IC 50 titers measured on the rebound viruses were similar to those found among the corresponding individual's latent viruses (Fig. 2c, red circles) . We conclude that the circulating latent viruses isolated by Q 2 VOA are representative of the overall neutralization profile present within the latent reservoir.
Rebound and latent viruses are distinct
Plasma rebound viruses isolated by SGA were compared to Q 2 VOA-derived latent viruses.
Although some rebound viruses were closely related to reservoir viruses in resistant participants, only 3 of 217 rebound env sequences obtained were identical to the 768 Q 2 VOA-derived latent viruses isolated from 9 participants ( Fig. 3 and Supplementary Fig 6) . Moreover, the 3 exceptions were all found in a single individual (participant 602) and represented only 9.7% of all rebound sequences isolated from that participant (Fig. 3) . Although the majority of analyzed participants harbored reservoirs dominated by expanded clones, these clones did not emerge in plasma upon treatment interruption. Strikingly, even a latent expanded clone with complete resistance to 3BNC117 could not be found among rebound viruses (Fig 3, participant 601 ).
3BNC117 resistance mutations in the latent reservoir
We compared the sequences of putative 3BNC117 target sites in env obtained from plasma rebound viruses to Q 2 VOA-derived sequences from the circulating reservoir for the presence of mutations (Bar et al., 2016; Caskey et al., 2015; Cheng et al., 2018; Lynch et al., 2015; Scheid et al., 2016) . Despite the lack of overlap between the rebound and latent viruses noted above, rebound viruses demonstrated nucleotide and corresponding amino acid variants in the 3BNC117 binding site that preexisted in the latent reservoir. These variants were often present at low frequencies in the reservoir and enriched in rebound viruses ( Figure 4 , red arrows). For example, all rebound sequences from participant 601 contain an isoleucine at position 459, compared to 33 percent of sequences within the latent reservoir. In participant 609, all rebound sequences at position 371 contain a leucine, which is present in just a small minority of latent reservoir sequences. On the other hand, there were only 5 cases in which amino acid variants found in the majority of rebound sequences were not detected in the latent reservoir ( Figure 4 , black arrows). To examine the accumulation of mutations during ATI as a potential explanation for the divergence between latent and rebound viruses, we created a mathematical model to simulate this process ( Supplementary Fig. 8 ). For each participant we computed the frequency of mutations accumulated during the simulated rebound, where the time to rebound in simulation was within one week before or after the observed time to rebound for that participant ( Fig. 5a gray bars).
Using this model and including 868 env sequences from both near full-length sequencing and Q 2 VOA (Fig. 5a blue bars), we found only 7 rebound sequences that were within the number of expected mutations, and all of these were found in participant 602. We then analyzed latent and rebound sequences for the presence of recombination using the 3SEQ recombination algorithm (http://mol.ax/software/3seq/). We found statistical evidence of recombination (rejection of the null hypothesis of clonal evolution) among 7 of the 9 participants tested (Supplementary Table   7 ). In the majority of recombination events, the 2 "parent" sequences derived from the latent reservoir, and the "child" sequence was a rebound sequence; however, there were instances in which the parents were comprised of either a latent and rebound sequence or two rebound sequences ( Supplementary Fig. 7 , and Supplementary Table 8 ). Examples of recombinant rebound viruses are illustrated in Figure 5b . Of note, there was only a single instance among the 27 latent parents involved in recombination events in which the latent virus was an expanded clone. In this case (participant 613), the rebound virus that derived from this recombination event accounted for only 1 out of the 12 rebound viruses isolated. The other 11 rebound viruses derived from a recombination event between two latent viruses that were "singles"
(Supplementary Fig. 7 and Supplementary Tables 8 and 9 ). Taking into account the possibility of recombination, the observed distance between latent and rebound viruses decreases, and is often close to the range predicted by the mutation simulation model described above (Fig. 5a yellow bars). We conclude that in addition to the accumulation of mutations during ATI, recombination may account for the considerable genetic distance between circulating latent and rebound virus.
Discussion
We enrolled 15 HIV-1-infected individuals to receive 2 doses of monoclonal antibody 3BNC117 over a 23-week period while on suppressive ART and to subsequently undergo ART interruption while receiving 2 additional doses of the antibody. Our analysis revealed that the size of the circulating reservoir is not altered during the 23-week observation period before ART interruption. However, the composition of the circulating latent reservoir varies significantly, in a way that is independent of the sensitivity of the latent viruses to 3BNC117. The neutralization profile obtained from the reservoir by Q 2 VOA is predictive of time to rebound, and rebound virus amino acid variants are frequently pre-existing within the latent reservoir. Finally, although the rebounding viruses are typically absent from the circulating latent reservoir, the sequences of rebound viruses frequently correspond to latent virus recombinants.
Antibody monotherapy in the absence of ART delays viral rebound and selects for antibodyresistant viruses (Caskey et al., 2015; Caskey et al., 2017; Scheid et al., 2016) . When participants in a prior trial were pre-screened for sensitivity and received infusions of 3BNC117 at time 0 and 1 3 regimen was administered in the setting of the ATI in the current study, but in participants who
were not pre-screened for sensitivity. Rebound was delayed for an average of 5.5 weeks, and an analysis of the reservoir by Q 2 VOA revealed that the delay in rebound by 3BNC117 monotherapy is directly related to the sensitivity of T cell derived outgrowth viruses found in the circulating reservoir. Thus, the outgrown viruses obtained by Q 2 VOA are representative of the neutralization profile of the clinically relevant latent reservoir.
The size of the latent reservoir remains relatively constant over time, with a calculated half-life of 3.6 years (Crooks et al., 2015; Finzi et al., 1999) . However, the discovery of replicationcompetent clones suggested a dynamic reservoir (Cohn and Nussenzweig, 2017; Kwon and Siliciano, 2017) , and clones of T cells bearing integrated viruses have been reported to expand and contract over periods of years (Cohn et al., 2015; Wang et al., 2018) . Expression of viral env in individuals on suppressive ART is limited, and neither 3BNC117 nor VRC01 (Lynch et al., 2015) infusion altered the size of the HIV reservoir in this setting. Nevertheless, there was significant fluctuation in the distribution of circulating latent viruses over the 6-month period before ART interruption that was not directly related to 3BNC117 sensitivity. These changes could be due to homeostatic proliferation, stimulation by cognate antigen, or cell death. For example, an influenza-specific CD4 + T cell clone that harbors a latent virus might expand after vaccination or exposure to the pathogen and later contract. Alternatively, the observed differences could simply be due to changes in the specific T cell clones that happen to be in circulation at the 2 time points. Our finding that the distribution of circulating clones of latent cells can change dramatically in a relatively short period of 6 months indicates that the circulating reservoir is far more dynamic than previously appreciated. Table 4 , Supplementary Fig. 6 ). Thus, there is good concordance between the near full-length DNA assay and Q 2 VOA.
Although we obtained an average of 80 latent HIV-1 sequences for each participant, and 57% of these were clonal, we only found three instances in which the rebounding virus was identical to a virus in the latent reservoir. However, 3BNC117 binding site nucleotide and amino acid variants found in rebound sequences were frequently preexisting in the latent reservoir. The observations that rebound viruses are unique but contain specific mutations found in the reservoir appear to be at odds but can be explained at least in part by recombination between viruses.
Recombination is a major source of HIV-1 diversity (Burke, 1997; Robertson et al., 1995) .
Recombination occurs when two RNA strands from different viruses co-infect a single cell, wherein recombinant genomes are generated by reverse transcriptase template switching. HIV-1 recombination rates have been estimated at ~1.4 x 10 -5 to 1.38 x 10 -4 events per base per generation (Batorsky et al., 2011; Neher and Leitner, 2010; Shriner et al., 2004) . This rate is within range of that of reported HIV mutation rates (Abram et al., 2010; Ji and Loeb, 1992;  1 5
Larder , 1995; Moutouh et al., 1996) , CD8 + T cells (Ritchie et al., 2014; Streeck et al., 2008) , and autologous neutralizing antibodies (Chaillon et al., 2013; Moore et al., 2013; Song et al., 2018 The quantitative and qualitative viral outgrowth assay (Q 2 VOA) was performed utilizing PBMC isolated by leukapheresis, as previously described (Lorenzi et al., 2016) . Q 2 VOA isolates replication-competent viruses from the latent reservoir using a limiting dilution method such that each virus likely originates from a single reactivated infectious provirus. The frequency of latently infected cells was calculated using the IUPMStats v1.0 (http://silicianolab.johnshopkins.edu) (Rosenbloom et al., 2015) .
Viral neutralization testing by TZM.bl neutralization assay
Supernatants from p24 positive Q 2 VOA wells were tested against a panel of broadly neutralizing
antibodies by the TZM.bl neutralization assay, as described (Li et al., 2005; Montefiori, 2005) .
Neutralization assays were conducted in a laboratory meeting Good Clinical Laboratory Practice (GCLP) Quality Assurance criteria (Michael S. Seaman, Beth Israel Deaconess Medical Center).
Measurement of 3BNC117 serum levels by TZM.bl neutralization assay
Serum concentrations of 3BNC117 were measured at multiple time points post-infusion using a validated luciferase-based neutralization assay in TZM.bl cells as previously described (SarzottiKelsoe et al., 2014) . Briefly, serum samples were tested using a primary 1:20 dilution with 5-fold titration series against HIV-1 Env pseudovirus Q769.d22, which is highly sensitive to neutralization by 3BNC117. Env pseudoviruses were produced using an ART-resistant backbone vector that reduces background inhibitory activity of antiretroviral drugs if present in the serum sample (SG3ΔEnv/K101P.Q148H.Y181C, M. Seaman unpublished data). 3BNC117 clinical drug product was also tested in every assay set-up using a primary concentration of 10 μg/ml with 5-fold titration series. The serum concentration of 3BNC117 for each sample was calculated as follows: serum ID 50 titer (dilution) x 3BNC117 IC50 titer (μg/ml) = serum concentration of 3BNC117 (μg/ml). Murine leukemia virus (MuLV) was utilized as a negative control. All assays were performed in a laboratory meeting GCLP standards. The half-life of 3BNC117 was calculated using Phoenix WinNonLin Build 8 (Certara).
Bulk Cultures
We performed bulk viral outgrowth cultures using PBMCs harvested at week -2, and from rebound samples as described (Caskey et al., 2015) . Sequence analysis on bulk culture viruses was performed as previously described (Lorenzi et al., 2016) .
Single-genome amplification (SGA) of plasma rebound virus env genes
Single-genome amplification and sequencing of HIV-1 env genes was performed as previously described (Caskey et al., 2017; Salazar-Gonzalez et al., 2008; Scheid et al., 2016) . 
Near full-length genome analysis
Genomic DNA was extracted from 1-10×10 6 CD4 + T cells from week 23 leukapheresis samples.
DNA was subjected to limiting-dilution PCR using semi-nested primers in the gag gene 3GagININ 5'-GGGGCTGTTGGCTCTGGT-3' (Bruner et al., 2016; Ho et al., 2013) . PCR products were visualized and quantified using 1% 96-well E-Gels (Invitrogen). DNA dilutions wherein < 30% of the gag PCR wells were positive, were selected for further analysis because they have a > 90% of probability of containing single copy of HIV DNA in each PCR reaction based on the Poisson distribution. Near full-length outer PCR was performed and 1μl aliquots subjected to nested env PCR (Ho et al., 2013; Li et al., 2007) . Samples containing approximately 2600bp env amplicons were subjected to four segment PCR (A, B, C, D) (Ho et al., 2013) .
Samples containing either segment A+C, or A+D, or B+C, or B+D were subjected to library preparation and sequencing (Lorenzi et al., 2016) . Sequence adapters were removed using 1 Cutadapt v1.9.1 and read assembly for each virus was performed in three steps: 1. de novo assembly was performed using Spades v3.9.0 to yield long contig files; 2. Contigs longer than 255bp were aligned to an HIV full genome reference sequence and a consensus sequence was generated using Mira assembly v4.0.2; 3. Reads were re-aligned to the consensus sequence to close gaps, and a final read consensus was generated for each sequence. Sequences with double peaks (cutoff consensus identity for any residue <75%), stop codons, or shorter than the expected near full genome size were omitted from downstream analyses.
3BNC117 binding site analysis
All env sequences were translated to amino acids and aligned using ClustalW (Larkin et al., 2007) . The HXB2 (K03455) env sequence was used as a reference for numbering the amino acids. Frequency plots were produced for each env position targeted by 3BNC117 (Zhou et al.,
2013).
Clonal fluctuation calculation
Clonal composition shifts between time points in individual participants. We employed a statistical test to gauge whether such changes in composition could be explained by finite sampling alone, or whether they indicated real changes in the relative proportions of each clone in the reservoir. For this analysis, the counts for all sequences that were only observed once across time points were merged together in a group of "singles." All other sequence counts were considered separately. We used Fisher's exact test, implemented in R, to determine whether the counts of each clone (including the singles) observed at each time point were consistent with a single underlying distribution for both time points. IUPM were inferred for each clone based on the particular Q 2 VOA run from which each member of the clone was isolated, as previously described (Lorenzi et al., 2016) . Bayesian Markov chain Monte Carlo was implemented in Stan, using four separate chains of 10 5 iterations. The first 50000 iterations for each chain were discarded as warm-up.
Simulation of mutation accumulation during rebound
Rebounding viral sequences were rarely identical to those observed in viral outgrowth assays or by near full-length sequencing. To understand whether the differences between rebound sequences and those in the observed reservoir might be attributed to mutations accumulated during the rebound process, or whether the rebound virus was instead likely to have originated from clones that were not previously observed we developed a stochastic mutation simulation model. In addition to this simple model tracking the number of latent and actively infected cells, we also consider evolution of the virus at the sequence level. In order to compare with the data obtained in this study, we assume a sequence length for Env of 2600 base pairs. We are specifically interested in the accumulation of de novo mutations during the rebound process. We therefore treat the length 2600 sequences as binary, where zeros represent nucleotides that are the same as the source sequence from the latent reservoir, and ones represent a mutation. This approximation is justified because the number of mutations observed is much smaller than the length of the sequence, and thus the probability of back mutations is very small. We assume that mutations occur during the reverse transcription process, when new infection events occur after an actively 2 4
infected cell bursts. The probability of mutation per site per new infection event is 3×10
-5 (Sanjuan et al., 2010) . In addition we allow for the possibility of recombination between sequences, with a probability of crossover between strands of 1.4×10 -5 per site per new infection event (Neher and Leitner, 2010) . This probability also implicitly includes the probability of coinfection of a single host cell.
For simplicity, we assume that mutations have no effect on the fitness (or replication rate) of the virus. However, it is known that nonsynonymous mutations are often strongly deleterious, including in HIV (Haddox et al., 2016; Loeb et al., 1989; Louie et al., 2018; Zanini et al., 2017) .
Thus, our assumption of neutrality likely overestimates the true number of mutations that would be accumulated during the rebound process.
We simulate this stochastic rebound process until either the number of actively infected cells reaches 3×10 5 , corresponding roughly to a threshold of detection for virus in the blood around 200 copies mL -1 (Hill et al., 2014) , or until the total simulation time reaches 100 days. We repeated these simulations using 10 4 random sets of parameters as described above. Different parameter choices and stochastic effects lead to a range of observed rebound times ( Supplementary Fig. 8 ). At the end of each simulation, we also record the distribution of the number of mutations accumulated during the rebound process. As expected, the average number of accumulated mutations in the rebound sequences increases with the rebound time, though there is substantial stochastic variation ( Supplementary Fig. 8 ).
Distance, recombination snippet
In order to conservatively estimate the true distance (in terms of number of mutations) between rebound sequences and those in the reservoir, we counted each observed variant in rebound sequences as a mutation only if it did not match with any of the nucleotides at that site in the observed reservoir sequences. This prevents us from computing spuriously large mutational distances simply due to recombination between diverse sequences in the reservoir during the rebound process. The estimated rate of recombination in HIV is high, comparable to the mutation rate (Neher and Leitner, 2010) , and thus the possibility of recombination cannot be simply neglected. Indeed, tests for signatures of recombination (Lam et al., 2018) in the rebound sequences found multiple likely recombination events for all patients in this study except for 603 and 610.
Code availability
Code used for these simulations is available on GitHub at https://github.com/bartonlab/simplerebound-simulation.
Data availability
Sequence data that support the findings of this study have been deposited in GenBank with the accession codes pending. 
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